Antisense therapy for hormone-regulated tumors

Details Antisense therapy for hormone-regulated tumors Antisense therapy for hormone-regulated tumors

2007-11-20

2007-11-20

Schultz, J. Douglas (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024500, C435S006120, C435S375000

Reexamination Certificate

active

09619908

ABSTRACT:
A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No. 1), which is derived from the murine gene sequence, and CGCGGTGAGCAACACCAT (Seq. ID. No. 3) and AGGTCATGCAGCAGCCGC (Seq. ID No 4), which are derived from the human gene sequence.

REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 2003/0087857 (2003-05-01), Freier
patent: 2090702 (1992-03-01), None
patent: 2090705 (1992-03-01), None
Reuters New release, Mar. 17, 2003. Lily, Isis Drug Fails in Trial.
Sudhir Agrawal, Antisense Oligonucleotides: towards clinical trials, TIBTECH, Oct. 1996, vol. 14, pp. 376-387.
Alan M. Gewirtz et al., Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 3161-3163, Apr. 16, 1996.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23—Feb. 1998, pp. 45-50.
Ingo Tamm et al., Antisense therapy in oncology: new hope for an old idea? The Lancet, vol. 358, Aug. 11, 2001, pp. 489-497.
Hideaki Miyake, Michael Pollak, and Martin E. Gleave, Castration-induced Up-Regulation of Insulin-like Growth Factor Binding Protein-5 Potentiates Insulin-like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models, Cancer Research 60, 3058-3064, Jun. 1, 2000.
Christopher W. Gregory, Desok Kim, Ping Ye, A Joseph D'Ercole, Thomas G. Pretlow, James L. Mohler, and Frank S. French: Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft, Endocrinology, vol. 140, No. 5, 1999.
Hideaki Miyake, Colleen Nelson,, Paul S. Rennie, and Martin E. Gleave; Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3'-Kinase Pathway; Endocrinology, vol. 141, No. 6, 2000.

Affiliated with

Also associated with

Rating

Antisense therapy for hormone-regulated tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense therapy for hormone-regulated tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense therapy for hormone-regulated tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3837394